Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649673 · ClinicalTrials.gov registry record · Phase 1
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
A Phase 1 study, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02649673 is a Phase 1 study that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 34 participants.
The verdict
NCT02649673, a Phase 1 study, was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This trial will investigate the combination of two anti-cancer agents to treat patients with relapsed/refractory small cell lung cancer (SCLC) and ovarian cancers. Oral topotecan has US FDA approval for treating select gynecological cancers and SCLC. LCL161 is an investigational product that has been shown in clinical trials to work together with other anti-cancer agents. In this trial, investigators will determine the optimal dose of LCL161 and topotecan to administer to patients with relapsed/refractory SCLC and ovarian cancers, and examine the safety profile of the drug combination.
Interventions
- DRUG Topotecan
- DRUG LCL161
- DRUG Pegylated GCSF (PEG-GCSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-03-23 |
| Est. Completion | 2021-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649673
The ClinicalTrials.gov registry entry for NCT02649673 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Topotecan is the first listed.
NCT02649673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02649673 about?
NCT02649673 is a clinical study titled "LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies". This trial will investigate the combination of two anti-cancer agents to treat patients with relapsed/refractory small cell lung cancer (SCLC) and ovarian cancers. Oral topotecan has US FDA approval for treating select gynecological cancers and SCLC. LCL161 is an investigational product that has bee...
What is the current status of trial NCT02649673?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2016-03-23. Estimated completion is 2021-07-30.
What interventions are being tested in trial NCT02649673?
The interventions under investigation include: Topotecan (DRUG), LCL161 (DRUG), Pegylated GCSF (PEG-GCSF) (DRUG).
Who is sponsoring clinical trial NCT02649673?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.